Boltz, the AI that designs drug candidate molecules by computer, secures 6 pharma customers and raises $110 million in funding(wowtale.net)
Writing language: KoreanRead in the original language
Plain summary
- Boltz builds AI that predicts the shape of biomolecules such as proteins and small molecules and where they bind, and designs new molecules. Researchers use it on the 'Boltz Lab' platform and pay per molecular token, depending on the workload.
- Boltz-1, Boltz-2 and BoltzGen release their code and weights, so anyone can download and use them. The 2 proprietary models that appeared in June are not open models. The company disclosed results from the proprietary models but did not reveal the targets or figures.
- According to the company, the molecular tokens processed for paying customers have grown 50 times since June. It did not say whether the growth came from proprietary or open models. Its customers include 6 of the world's top 20 pharma companies.
- Pfizer builds a dedicated model from its past drug development data and owns the molecules it discovers. The Series A was led by Bessemer Venture Partners, and the valuation was not disclosed. Competitor Chai Discovery raised $400 million in July.
Found on
와우테일 ↗ / Published by source
Have you run into something like this? Tell us in a line or two what you did. You do not need to know the product.